How the Precise Habitats Can Predict the IDH Mutation Status and Prognosis of the Patients With High-grade Gliomas
NCT04908267 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2023-01-11
Summary
High-grade glioma is the most common primary malignant tumor in central nervous system, and its high tumor heterogeneity is the main cause of tumor progression, treatment resistance and recurrence. Habitat imaging is a segmentation technique by dividing tumor regions to characterize tumor heterogeneity based on tumor pathology, blood perfusion, molecular characteristics and other tumor biological features.
In some studies, the Hemodynamic Multiparametric Tissue Signature (HTS) method has been proven to be feasible. The Hemodynamic Multiparametric Tissue Signature (HTS) consists of a set of vascular habitats obtained by Dynamic Susceptibility Weighted Contrast Enhanced Magnetic Resonance Imaging (DSC-MRI) of high-grade gliomas using a multiparametric unsupervised analysis method. This allowed them to automatically draw 4 reproducible vascular habitats (High-angiogenic enhancing tumor; Low-angiogenic enhancing tumor; Potentially tumor infiltrated peripheral edema; Vasogenic peripheral edema) which enable to describe the tumor vascular heterogeneity robustly.
In other studies, contrast-enhancing mass can divided into spatial habitats by K-means clustering of voxel-wise apparent diffusion coefficient (ADC) and cerebral blood volume (CBV) values to observe the changes of voxels in spatial habitat on the time line. Using this so-called spatiotemporal habitat to identify progression or pseudoprogression in cancer therapy.
Above all, we have sufficient and firm reasons to deem that habitat imaging based on multiparametric MRI is more conducive to reflect the potential biological information inside the tumor and realize individualized diagnosis and treatment.
To sum up, the assumption of this experiment is that the Habitats Created by preoperative or postoperative Multiparametric MRI ,such as conventional MRI sequences, Dynamic Susceptibility Weighted Contrast Enhanced Magnetic Resonance Imaging (DSC-MRI), Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI), Diffusion Weighted Magnetic Resonance Imaging(DWI) ,Vessel Size Imaging (VSI) ,or Magnetic Resonance Spectroscopy (MRS) can predict the molecular mutation status, prognosis, treatment residence, progression, pseudoprogression, and even recurrence and distant intracranial recurrence in patients with high-grade gliomas.
Conditions
- High-grade Glioma
Sponsors & Collaborators
-
Weiguo Zhang
lead OTHER
Principal Investigators
-
Weiguo Zhang, Ph.D · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-08-01
- Primary Completion
- 2024-12-31
- Completion
- 2024-12-31
Countries
- China
Study Locations
More Related Trials
-
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
NCT00870129 ·Status: RECRUITING ·Phase: NA
-
Automatic Segmentation MRI Cerebral Glioma
NCT04674579 ·Status: UNKNOWN
-
Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning
NCT05624736 ·Status: UNKNOWN
-
PET (FDG)-MR Imaging for the Adult Patients Presented With Brain Tumor
NCT02071017 ·Status: UNKNOWN
-
Permeability Map to Distinguish Progression From Pseudoprogression in High-Grade Glioma
NCT01499823 ·Status: UNKNOWN
-
Study on Radiogenomics Features Associated With Radiochemotherapy Sensitivity in Gliomas
NCT06454097 ·Status: RECRUITING ·Phase: NA
-
MRS of Glioma Genomics
NCT05700071 ·Status: RECRUITING ·Phase: NA
-
fMRI Study of Functional Reorganization in Glioma Patients
NCT05019196 ·Status: UNKNOWN
-
Multimodality Imaging Combined With Multiple Targets Pathological Examination for Detecting of Biological Borders of Gliomas: a Clinical Application Study
NCT02941302 ·Status: UNKNOWN ·Phase: NA
-
Whole-Brain Tumor Burden Metrics with Inflammatory and Molecular Markers to Predict Postoperative Neurocognitive Decline in Glioma
NCT06885333 ·Status: COMPLETED
-
Differentiation of Progression From Treatment Effects in High-Grade Gliomas: A Clinical Trial With Multimodality MR Imaging
NCT03102203 ·Status: UNKNOWN
-
Protocol to Distinguish Tumor Recurrence From Treatment-Related Necrosis in Patients With High Grade Gliomas
NCT00942760 ·Status: COMPLETED
-
Radiogenomic and Prognosis Analysis in Glioma
NCT04122521 ·Status: UNKNOWN
-
Non Invasive IDentification of Gliomas With IDH1 Mutation
NCT01703962 ·Status: COMPLETED
-
Study About the Validity of MRS-guided Resection on Prognosis High-grade Glioma Gliomas
NCT02795364 ·Status: UNKNOWN ·Phase: NA
-
Combing a Deep Learning-Based Radiomics With Liquid Biopsy for Preoperative and Non-invasive Diagnosis of Glioma
NCT05536024 ·Status: UNKNOWN
-
Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery
NCT01417507 ·Status: COMPLETED
-
Assessment of Eloquent Function in Brain Tumor Patients
NCT01535430 ·Status: RECRUITING
-
Visual Study of Molecular Genotype in Glioma Evolution
NCT03750890 ·Status: UNKNOWN
-
MR Textural Analysis in Low Grade Gliomas
NCT04719806 ·Status: COMPLETED
-
Evaluation of the Use of Radiomics in 18F-FDOPA PET Examinations for the Characterization of Gliomas
NCT04469244 ·Status: COMPLETED
-
Improving Surgical Outcomes in Patients With Low Grade Gliomas Using Advanced Pre- and Intra-operative MRI
NCT02884947 ·Status: COMPLETED
-
Amino Acid PET to Assess the Efficacy of IDH Inhibitor Treatments for IDH Mutated Gliomas
NCT07017790 ·Status: NOT_YET_RECRUITING
-
A Nomogram for Predicting the Diagnosis of Central Malignant Tumors Based on Preoperative Clinical Characteristics and Laboratory Indicators:
NCT06914700 ·Status: COMPLETED
-
Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over
NCT02892708 ·Status: COMPLETED ·Phase: PHASE3